Korea Research Institute of Bioscience and Biotechnology

Other

Chung Ang University Industry Academic Cooperation

Angiolab, Inc.

Leadbio, Inc.

Hyun Ah Kang

Sang Ki Rhee

Doo-Byoung Oh

Hye Yun Moon

Jeong-Yoon Kim

Joo Hyung Heo

Jeong Seok Park

Eun Jung Kim

Doo Byoung Oh

Moo Woong Kim

Hong Jin Kim

Min-Young Kim

Jae Kap Jeong

Seonghun Kim

Eun-Kyu Park

Chang Seo Park

Eui Sung Choi

Jung Hoon Sohn

Hye-Yun Moon

Ohsuk Kwon

Jeong-Nam Park

Yunkyoung Song

Jae-Young Chang

Jung Hoon Bae

Disclosed is a gene multiple insertion cassette set including rDNA NTS fragments and an auxotrophic selection marker having an incomplete promoter is developed, and a safe oral recombinant strain having no antibiotic resistant marker is constructed by multiple insertion of an optimum number of the developed gene multiple insertion cassette sets into chromosomes of astrain, a vaccine composition including, as an active ingredient, the above strain, a culture product thereof, a cell lysate, or nodavirus capsid protein (NNVcp) isolated and purified therefrom, and a composition for feed addition including, as an active ingredient, the above strain, a culture product thereof, a cell lysate, or squalene or oxidosqualene isolated and purified therefrom.

rDNA NTS-based gene multiple insertion cassette set and GRAS-grade recombinant yeast strain

The present invention relates to a process for producing a human-type glycoprotein having reduced glycosylation by genetically manipulating an enzyme involved in glycosylation using asystem. In detail, the present invention relates to a process for producing a human-type glycoprotein by identifying a dolichyl-phosphate-mannose dependent &#x3b1;-1,3-mannosyltransferase gene from, constructing amutant strain producing a glycoprotein exhibiting reduced glycosylation by disrupting the identified gene, and subjecting the mutant strain to various genetic manipulations for the synthesis of human-type glycan.

[object Object]

The present invention relates to a novelgene regulating Unfolded Protein Response (UPR) and a method for improving the efficiency of secretory expression of a recombinant protein using the same, more particularly, a method for improving the efficiency of secretory expression of a recombinant protein by identifying, modifying, and optimizing the HpHAC1 gene, which encodes a key transcription regulatory factor of the UPR mechanism in, and a regulatory mechanism mediated by the gene. According to the present invention, the secretory expression system ofcan be used for the mass-production of secretory proteins for industrial and medical applications, thereby producing a large amount of the proteins at low cost. Accordingly, the method is employed in the production of the proteins for industrial and medical use, so as to reduce economic burden for a patient, and contribute to the improvement in the welfare of all mankind.

The present invention relates to beta-galactosidase derived from, a BgaC protein exhibiting the enzyme activity, and a method for using the same. The protein can be used in the modification and analysis of sugar chain and used as an anti-cancer agent.

The present invention relates to a process for producing a human-type glycoprotein having reduced glycosylation by genetically manipulating an enzyme involved in glycosylation using asystem. In detail, the present invention relates to a process for producing a human-type glycoprotein by identifying a dolichyl-phosphate-mannose dependent &#xa5;&#xe1;-1,3-mannosyltransferase gene from, constructing amutant strain producing a glycoprotein exhibiting reduced glycosylation by disrupting the identified gene, and subjecting the mutant strain to various genetic manipulations for the synthesis of human-type glycan.

The present invention relates to a novel YlMPO1 gene which plays an important role in mannosylphosphorylation of an industrial yeastand to a method for preparing a host system capable of producing recombinant glycoproteins free of mannosylphosphate by disruption of the gene. The mannosylphosphorylation is suppressed by the disruption of YlMPO1 gene according to the present invention, thereby achieving humanization of glycosylation pathway of

YLMPO1 gene derived from yarrowia lipolytica and a process for preparing a glycoprotein not being mannosylphosphorylated by using a mutated yarrowia lipolytica in which YLMPO1 gene is disrupted

The present invention provides a human serum albumin-TIMP2 fusion protein having the amino acid sequence set forth in SEQ ID NO. 10, a polynucleotide encoding the same and a vector comprising the polynucleotide, a host cell transformed with the vector, a method for producing the human serum albumin-TIMP2 fusion protein and a pharmaceutical composition comprising the human serum albumin-TIMP2 fusion protein. The human serum albumin-TIMP2 fusion protein is stable and retains the activity of TIMP2, thus it can be used as a pharmaceutical composition to treat diseases related to angiogenesis and/or metastasis of cancer cells.

Human serum albumin-TIMP2 fusion protein, a polynucleotide encoding the same and a method of producing the human serum albumin-TIMP2 fusion protein

Expression cassettes for transforming and their use are disclosed. The present invention relates to expression cassettes containing ribosomal DNA fragment, CYH gene resistant to cycloheximide, and a desired gene. Expression cassette further comprising GAPDH promoter gene which allows an increase in the expression of the desired gene also provided. Moreover, the present invention provides a process for producing tetraacetyl phytosphingosine using transformed cells with the expression cassettes in a higher yield.

Plasmid for gene expression in pichia ciferrii and transformation method using the same

Growing community of inventors

Daejeon, South Korea

Hyun Ah Kang